Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rubicon ResearchNSE:RUBICON +0.36%19 Dividend Yield % is 0.08% as of Sep. 03, 2026. GuruFocus rates NSE:RUBICON with a GF Score™ of 19/100. The stock has 5 warning signs investors should review. Among 508 Drug Manufacturers companies, Rubicon Research ranks worse than 98.03% on this metric.
As of today (2026-09-03), the Trailing Annual Dividend Yield of Rubicon Research is 0.08%.
The historical rank and industry rank for Rubicon Research's Dividend Yield % or its related term are showing as below:
NSE:RUBICON'
s Dividend Yield % Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.08
Current: 0.08
During the past 4 years, the highest Dividend Yield of Rubicon Research was 0.08%. The lowest was 0.00%. And the median was 0.00%.
NSE:RUBICON's Dividend Yield % is ranked worse than 98.03% of 508
companies
in the Drug Manufacturers industry
Industry Median: 2
vs NSE:RUBICON: 0.08
Rubicon Research (NSE:RUBICON) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
The historical data trend for Rubicon Research's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:RUBICON vs LLY, JNJ, ABBV: Dividend Yield % Comparison
For the Drug Manufacturers - General subindustry, Rubicon Research's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rubicon Research Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rubicon Research's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Rubicon Research's Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Rubicon Research Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
INR 1.500000
2026-08-07
2026-08-07
0000-00-00
Cash Dividend
annually
INR:INR 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Rubicon Research's Trailing Annual Dividend Yield (%) for Today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rubicon Research (NSE:RUBICON) has a Dividend Yield % of 0.08% as of Sep. 03, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Rubicon Research and its competitors. According to the industry distribution chart, Rubicon Research ranks #498 out of 508 companies in the Drug Manufacturers industry, placing it in the top 98%.
Is Rubicon Research's Dividend Yield % too high?
Rubicon Research's current Dividend Yield % is 0.08%. The Drug Manufacturers industry median Dividend Yield % is 2.00. Rubicon Research's value of 0.08% is 96% below this industry median. Based on the distribution chart, Rubicon Research ranks #498 out of 508 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Rubicon Research has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Rubicon Research's Dividend Yield % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Rubicon Research ranks #498 out of 508 companies for Dividend Yield %. This places Rubicon Research in the lower half of its industry. The industry median Dividend Yield % is 2.00. Rubicon Research's value of 0.08% is 96% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Drug Manufacturers company?
The median Dividend Yield % among Drug Manufacturers companies is 2.00, based on 508 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rubicon Research's current Dividend Yield % of 0.08% is 96% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Rubicon Research and its competitors. For the Drug Manufacturers industry, the median Dividend Yield % is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rubicon Research's current Dividend Yield % is 0.08%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rubicon Research stock overvalued right now?
Rubicon Research (NSE:RUBICON) has a current Dividend Yield % of 0.08%. The current Dividend Yield % is 0.08% and 96% below the Drug Manufacturers industry median of 2.00. Rubicon Research's overall GF Score™ is 19/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Rubicon Research (NSE:RUBICON), the current Dividend Yield % is 0.08% as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rubicon Research Ltd is a pharmaceutical formulations company specializing in developing, manufacturing, and marketing branded specialty and generic prescription products. Starting as a provider of contract formulation development services, the company expanded to operate an oral solids manufacturing facility in India, offering contract development and manufacturing services for regulated markets. The company's diverse product portfolio covers multiple therapeutic areas, including analgesics and pain management, CVS, CNS, hypokalemia, skeletal muscle relaxants, NRT, gastrointestinal, metabolic, and immunosuppressants. The company operates in India, the USA, and other markets, with the majority of its revenue coming from the USA.
19GF Score
Get the complete analysis for NSE:RUBICON
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:RUBICON has been successfully added to your 
